Bristol Myers Squibb (BMY) Revenue (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Revenue data on file, last reported at $11.5 billion in Q1 2026.

• Revenue for Q1 2026 came in at $11.5 billion, up 2.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.5 billion (up 1.78% YoY), and the FY2025 annual result was $48.2 billion, changed 0.22% from the prior year.
• Revenue retreated to $11.5 billion in Q1 2026 per BMY's latest filing, from $12.5 billion in the prior quarter.
• Over five years, Revenue peaked at $12.5 billion in Q4 2025 and troughed at $11.0 billion in Q3 2023.
• A 5-year average of $11.7 billion and a median of $11.6 billion in 2022 frame the typical range for Revenue.
• The sharpest annual moves came in 2024 and 2025: Revenue advanced 8.69% in 2024, then fell 5.6% in 2025.
• A 5-year view of Revenue shows it stood at $11.4 billion in 2022, then advanced by 0.62% to $11.5 billion in 2023, then advanced by 7.54% to $12.3 billion in 2024, then increased by 1.3% to $12.5 billion in 2025, then dropped by 8.1% to $11.5 billion in 2026.
• Business Quant data shows BMY's Revenue at $11.5 billion in Q1 2026, $12.5 billion in Q4 2025, and $12.2 billion in Q3 2025.